Investor Presentaiton

Growth Opportunities Outside of the USA • • • no During H1FY24 Nova Eye has invested in market access in key territories outside the USA. New investment in sales infrastructure offers growth opportunities. Western Europe and Canada markets with product registrations, reimbursement and sales channel in place: Germany (via hybrid direct and distributor channel), UK (iTrack TM Advance NHS and NICE approved), Spain, Italy, Poland, Switzerland, UAE and Canada (via hybrid direct and distributor channel) - China approvals in place, approval iTrack TM Advance pending. Established distributor with early market penetration temporarily disrupted in 2023 by medical industry-wide government review of marketing methods. South Korea - sales channel in place and registration for iTrack TM Advance pending. Singapore - Hybrid direct and distributor sales channel. Singapore is an important reference market in driving procedural adoption throughout South-East Asia. Market access work complete; these markets offer growth opportunities USA Scale existing commercial infrastructure for growth Growth Market The glaucoma surgical device market in Western Europe is expected to grow at a CAGR of 16% to 2028 and is currently valued at US$114m per annum(¹). (1) Marketscope 2023 Glaucoma Surgical Device Market Report, 2024 estimate and 2028 estimate incorporating stents, canal surgery and glaucoma drainage devices, growth through to 2028 Western Europe New iTrack Advance registration pending South Korea New iTrack Advance registration pending China iTrack Advance registration Singapore completed April 2023 nova-eye.com | 15

View entire presentation